Who
Hongbo Lu
Director
Company insider
Files Form 4 as: Director, Zenas BioPharma; Director, Arrowhead Pharmaceuticals; Director, Terns Pharmaceuticals; Director, Avedro; Director, Turning Point Therapeutics.
In numbers
- Trades disclosed
- 51
- Buys
- 21
- Sells
- 1
- Bought
- $32.2M
- Sold
- $457K
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 19 Feb 2019
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $228K2,970 at $76.88 | filing |
| 12 May 2026filed 14 May 2026 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $228K2,970 at $76.88 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $70K3,768 at $18.63 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $70K3,768 at $18.63 | filing |
| 31 Mar 2026filed 31 Mar 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $1.5M75,000 at $20.00 | filing |
| 31 Mar 2026filed 31 Mar 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $1.5M75,000 at $20.00 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $585K25,985 at $22.50 | filing |
| 11 Feb 2026filed 13 Feb 2026 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $585K25,985 at $22.50 | filing |
| 16 Dec 2025filed 18 Dec 2025 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —7,819 at $0.00 | filing |
| 7 Oct 2025filed 9 Oct 2025 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $5.0M263,160 at $19.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 1 Feb 2025filed 3 Feb 2025 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,657 at $0.00 | filing |
| 18 Dec 2024filed 20 Dec 2024 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $385K16,733 at $22.99 | filing |
| 25 Sep 2024filed 15 Nov 2024 | ARWR Arrowhead PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —5,650 at $0.00 | filing |
| 13 Sep 2024filed 9 Oct 2025 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $1000K58,823 at $17.00 | filing |
| 13 Sep 2024filed 17 Sep 2024 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $1000K58,823 at $17.00 | filing |
| 12 Sep 2024filed 17 Sep 2024 | Terns Pharmaceuticals | SEC FORM 4 Bought | $2.0M190,476 at $10.50 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)ZBIO · themarketsdaily.com · 18 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head ReviewARWR · themarketsdaily.com · 18 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)ZBIO · themarketsdaily.com · 14 Oct 2026Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Break Below 200-Day Moving Average – Here's What HappenedARWR · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name Hongbo Lu; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.